[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628277":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":26,"locations":34,"responsibleParty":164,"collaborators":11,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":11,"eligibilityCriteria":172,"healthyVolunteers":168,"sex":173,"minAge":174,"maxAge":11,"enrollmentInfo":175,"targetDuration":11,"studyType":178,"phases":179,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":191,"whyStopped":11,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)","EXPERIMENTAL",null,[13],"Drug: Nivolumab + Relatlimab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Nivolumab + Relatlimab","Specified dose on specified days",[9],[21,22],"Relopduo","BMS-986213",[24],{"name":5,"affiliation":5,"role":25},"STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[35,51,64,76,88,101,110,122,131,143,155],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Local Institution - 0012","Nashik","Dādra and Nagar Haveli and Damān and Diu","422001","India","IN",{"type":43,"coordinates":44},"Point",[45,46],73.79096,19.99727,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0012",{"facility":52,"status":11,"city":53,"state":54,"zip":55,"country":40,"countryCode":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Local Institution - 0010","Mumbai","Maharashtra","400052",{"type":43,"coordinates":57},[58,59],72.88261,19.07283,{"lat":59,"lon":58},[62],{"name":63,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0010",{"facility":65,"status":11,"city":66,"state":54,"zip":67,"country":40,"countryCode":41,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Local Institution - 0009","Navi Mumbai","400614",{"type":43,"coordinates":69},[70,71],73.01582,19.03681,{"lat":71,"lon":70},[74],{"name":75,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0009",{"facility":77,"status":11,"city":78,"state":54,"zip":79,"country":40,"countryCode":41,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Local Institution - 0008","Pune","411017",{"type":43,"coordinates":81},[82,83],73.85535,18.51957,{"lat":83,"lon":82},[86],{"name":87,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"facility":89,"status":11,"city":90,"state":91,"zip":92,"country":40,"countryCode":41,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Local Institution - 0003","Bhubaneswar","Odisha","751007",{"type":43,"coordinates":94},[95,96],85.83385,20.27241,{"lat":96,"lon":95},[99],{"name":100,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0003",{"facility":102,"status":11,"city":90,"state":11,"zip":103,"country":40,"countryCode":41,"cosmosGeoPoint":104,"geoPoint":106,"contacts":107},"Local Institution - 0011","751019",{"type":43,"coordinates":105},[95,96],{"lat":96,"lon":95},[108],{"name":109,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0011",{"facility":111,"status":11,"city":112,"state":11,"zip":113,"country":40,"countryCode":41,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Local Institution - 0002","Chennai","600006",{"type":43,"coordinates":115},[116,117],80.27847,13.08784,{"lat":117,"lon":116},[120],{"name":121,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0002",{"facility":123,"status":11,"city":53,"state":11,"zip":124,"country":40,"countryCode":41,"cosmosGeoPoint":125,"geoPoint":127,"contacts":128},"Local Institution - 0006","400 012",{"type":43,"coordinates":126},[58,59],{"lat":59,"lon":58},[129],{"name":130,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0006",{"facility":132,"status":11,"city":133,"state":11,"zip":134,"country":40,"countryCode":41,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Local Institution - 0005","Nagpur","440001",{"type":43,"coordinates":136},[137,138],79.08491,21.14631,{"lat":138,"lon":137},[141],{"name":142,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0005",{"facility":144,"status":11,"city":145,"state":11,"zip":146,"country":40,"countryCode":41,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Local Institution - 0004","New Delhi","110029",{"type":43,"coordinates":148},[149,150],77.2148,28.62137,{"lat":150,"lon":149},[153],{"name":154,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0004",{"facility":156,"status":11,"city":145,"state":11,"zip":157,"country":40,"countryCode":41,"cosmosGeoPoint":158,"geoPoint":160,"contacts":161},"Local Institution - 0001","110085",{"type":43,"coordinates":159},[149,150],{"lat":150,"lon":149},[162],{"name":163,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":165,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628277","phase-4-a-study-to-assess-the-safety-and-tolerability-of-nivolumab--relatlimab-fixed-dose-combination-fdc-in-untreated-unresectable-or-metastatic-melanoma-participants-in-india-100628277",false,"NCT07459543","A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India","A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.","Inclusion Criteria\n\n\\- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\u002FLansky Performance Score ≥ 80% for minors (ages 12-17) ONLY.\n\nNote: Participants with ECOG PS 2 are allowed if the performance status of 2 is attributable to disease burden (and not to significant comorbidity), and if the investigator and Medical Monitor agree the patient may benefit from treatment.\n\n* Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) staging system (8th edition).\n* Participants must have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.\n* Participants must have completed prior radiotherapy at least 2 weeks prior to study treatment administration.\n* Individuals of Childbearing Potential (IOCBP) must not be pregnant or breastfeeding.\n\nExclusion Criteria\n\n* Participants must not have active brain metastases or leptomeningeal metastases.\n* Participants must not have uveal melanoma.\n* Participants must not have an active, known, or suspected autoimmune disease.\n\nNote: Participants may enroll with the following conditions:\n\ni) type 1 diabetes mellitus; ii) hypothyroidism only requiring hormone replacement; iii) skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; iv) conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n\n\\- Participants must not have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment.\n\nNote: Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n\n* Participants must not have a history of myocarditis.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","12 Years",{"count":176,"type":177},40,"ESTIMATED","INTERVENTIONAL",[180],"PHASE4","The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.",[183,184],"Unresectable Melanoma","Metastatic Melanoma",[186,187,188,40,189,190],"Skin Cancer","Malignant Melanoma","Immunotherapy","Nivolumab","Relatlimab","NOT_YET_RECRUITING","2026-08-10",{"date":194,"type":195},"2026-08-12","ACTUAL",{"date":197,"type":177},"2026-11-15",{"date":199,"type":177},"2029-05-28",{"name":5,"class":6},11]